A 20-site Mexico deployment gives IMEXHS its first true public-sector reference at scale
IMEXHS Limited (ASX:IME) has won a public tender to roll out its Aquila+ radiology platform across 20 hospitals and clinics in Zacatecas, Mexico. The deal adds about A$384,000 in new Annual Recurring Revenue plus a one-off A$50,000 implementation fee, secured through local distributor GOBA.
On its own, A$384k of ARR is not a number that re-rates a stock. But the shape of this deal is more interesting than the size. IMEXHS has bundled all five of its proprietary AI workflow agents with two Gleamer diagnostic algorithms, ChestView and Fracture Detection, into a single public-sector deployment.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
Agentic workflow tools, which are AI systems that automate steps a radiologist would otherwise do manually, plus embedded diagnostic AI across 20 public hospitals, is a denser AI stack than most peers have managed to land anywhere.
Implementation has already started, with rollout across all 20 sites targeted by end of June 2026 and full ARR run rate from September 2026. That timing matters for how investors should read the FY27 numbers.
Why a small contract is a meaningful proof point
The headline ARR is modest, but the reference value is not. Public tenders in Latin American healthcare are notoriously hard to win for foreign software vendors, and IME has now done it with a fully AI-loaded version of its platform.
We think the more useful read is that Zacatecas becomes a showcase site. Once 20 public hospitals are running Aquila+ with agentic AI and Gleamer algorithms live, IMEXHS has something concrete to walk into the next state-level procurement with.
Mexico has 32 federal entities. If the Zacatecas deployment runs cleanly, the sales motion into the next two or three states gets materially easier.
The Gleamer partnership is doing real work here
ChestView and Fracture Detection are not IMEXHS’s own algorithms. They come from French AI radiology specialist Gleamer, which means IMEXHS is selling a stack that combines its own workflow layer with best-of-breed third-party diagnostics.
That is a sensible architecture for a small-cap. Building diagnostic AI from scratch is capital-intensive and slow. Integrating Gleamer lets IMEXHS punch above its weight on capability without burning cash on duplicate R&D.
The risk worth flagging is reliance. If Gleamer’s economics or partnership terms shift, IMEXHS’s AI value proposition would need a quick rethink. For now though, the combination is the selling point.
What this does to the recurring revenue trajectory
IMEXHS has spent the last few years grinding ARR higher across Colombia, Australia and the US. A clean A$384k addition from a single Mexican state, with full run rate from September 2026, is exactly the kind of incremental win the model needs.
Our concern is that one tender does not make a pipeline. Investors will want to see at least one or two follow-on Mexican contracts in the next 12 months to confirm this is a repeatable motion rather than a one-off through GOBA.
The Investors Takeaway for IMEXHS
The Zacatecas win is small in dollar terms but strategically useful. It gives IME a public-sector reference, a working showcase of agentic AI plus Gleamer diagnostics, and a credible foothold in Mexico’s federal procurement landscape.
The real test is what lands in the next 12 months. If GOBA can convert this into one or two more state-level tenders by mid-2027, the Mexico story starts to look like a genuine growth leg rather than an opportunistic contract. Readers can find more in-depth coverage of ASX small-cap medical technology names at stocksdownunder.
